FrançaisAre analysts right about Acadia Pharmaceuticals (ACAD)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Acadia Pharmaceuticals, we replayed every analyst price target of the past 12 months and measured the real outcome: 32% were profitable, average return +11% (183 calls). At 3 months: +4% average return (50% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Cantor Fitzgerald | 24 | 38% | +6% |
| HC Wainwright & Co. | 19 | 26% | +3% |
| RBC Capital | 18 | 33% | +8% |
| Needham | 16 | 38% | +30% |
| JMP Securities | 15 | 20% | -12% |
Frequently asked questions
Is Acadia Pharmaceuticals a buy right now?
The analyst consensus on Acadia Pharmaceuticals (ACAD) is "Buy" (36 bullish, 0 bearish calls over 12 months). This is not advice: historically, 32% of their targets on this stock turned out profitable over 1 year.
What is Acadia Pharmaceuticals's price target?
The median 12-month price target is $36.00 (+21% vs $29.73), ranging from $25.00 to $49.00 (13 analysts).
Are analysts accurate on Acadia Pharmaceuticals?
Over 1 year, 32% of analyst targets on Acadia Pharmaceuticals were profitable, for an average return of +11% (across 183 timestamped calls). This is JPI Invest's accuracy metric.
What is the Acadia Pharmaceuticals stock forecast?
Analysts target a median of $36.00 within 12 months, i.e. +21% vs the current price. The most bullish targets $49.00, the most cautious $25.00.
What is the Acadia Pharmaceuticals stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $36.00, +21%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (32%), and the stock's past trajectory.
Is Acadia Pharmaceuticals overvalued?
Detailed valuation data for Acadia Pharmaceuticals is available in the interactive analysis.
📊 See the full interactive analysis of Acadia Pharmaceuticals →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.